Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 4.69 Billion USD | 1.31% |
| 2023 | 4.56 Billion USD | 21.74% |
| 2022 | 3.75 Billion USD | 60.04% |
| 2021 | 2.34 Billion USD | 13.57% |
| 2020 | 2.06 Billion USD | -21.01% |
| 2019 | 2.61 Billion USD | 13.1% |
| 2018 | 2.31 Billion USD | 29.01% |
| 2017 | 1.79 Billion USD | 3.62% |
| 2016 | 1.72 Billion USD | -0.44% |
| 2015 | 1.73 Billion USD | -34.12% |
| 2014 | 2.63 Billion USD | 1.97% |
| 2013 | 2.58 Billion USD | 1.6% |
| 2012 | 2.54 Billion USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 4.73 Billion USD | 3.68% |
| 2024 Q2 | 4.78 Billion USD | 1.01% |
| 2024 FY | 4.69 Billion USD | 2.85% |
| 2024 Q4 | 4.69 Billion USD | -2.67% |
| 2024 Q3 | 4.82 Billion USD | 0.9% |
| 2023 FY | 4.56 Billion USD | 21.74% |
| 2023 Q3 | 4.59 Billion USD | 3.93% |
| 2023 Q4 | 4.56 Billion USD | -0.61% |
| 2023 Q2 | 4.42 Billion USD | 12.37% |
| 2023 Q1 | 3.93 Billion USD | 4.49% |
| 2022 Q2 | 3.38 Billion USD | 44.1% |
| 2022 Q3 | 3.41 Billion USD | 0.86% |
| 2022 FY | 3.75 Billion USD | 60.04% |
| 2022 Q1 | 2.34 Billion USD | 0.17% |
| 2022 Q4 | 3.76 Billion USD | 10.34% |
| 2021 Q3 | 2.24 Billion USD | 1.21% |
| 2021 FY | 2.34 Billion USD | 13.57% |
| 2021 Q1 | 2.05 Billion USD | -0.63% |
| 2021 Q2 | 2.22 Billion USD | 8.33% |
| 2021 Q4 | 2.34 Billion USD | 4.24% |
| 2020 Q3 | 2.59 Billion USD | -4.35% |
| 2020 Q1 | 2.68 Billion USD | 2.9% |
| 2020 Q2 | 2.7 Billion USD | 0.69% |
| 2020 Q4 | 2.06 Billion USD | -20.29% |
| 2020 FY | 2.06 Billion USD | -21.01% |
| 2019 Q1 | 2.01 Billion USD | -12.9% |
| 2019 FY | 2.61 Billion USD | 13.1% |
| 2019 Q4 | 2.61 Billion USD | 33.45% |
| 2019 Q3 | 1.95 Billion USD | -1.67% |
| 2019 Q2 | 1.99 Billion USD | -1.04% |
| 2018 Q3 | 2.38 Billion USD | -1.13% |
| 2018 Q4 | 2.31 Billion USD | -3.12% |
| 2018 FY | 2.31 Billion USD | 29.01% |
| 2018 Q1 | 1.5 Billion USD | -15.97% |
| 2018 Q2 | 2.41 Billion USD | 60.28% |
| 2017 Q1 | 1.8 Billion USD | 4.41% |
| 2017 FY | 1.79 Billion USD | 3.62% |
| 2017 Q3 | 1.8 Billion USD | 2.22% |
| 2017 Q4 | 1.79 Billion USD | -0.91% |
| 2017 Q2 | 1.76 Billion USD | -2.03% |
| 2016 FY | 1.72 Billion USD | -0.44% |
| 2016 Q4 | 1.72 Billion USD | -0.46% |
| 2016 Q3 | 1.73 Billion USD | -1.16% |
| 2016 Q2 | 1.75 Billion USD | 1.43% |
| 2016 Q1 | 1.73 Billion USD | -0.24% |
| 2015 Q2 | 1.85 Billion USD | 5.51% |
| 2015 Q1 | 1.75 Billion USD | -33.48% |
| 2015 FY | 1.73 Billion USD | -34.12% |
| 2015 Q4 | 1.73 Billion USD | -1.65% |
| 2015 Q3 | 1.76 Billion USD | -4.56% |
| 2014 Q2 | 2.66 Billion USD | 2.25% |
| 2014 Q1 | 2.6 Billion USD | 0.88% |
| 2014 FY | 2.63 Billion USD | 1.97% |
| 2014 Q4 | 2.63 Billion USD | -0.35% |
| 2014 Q3 | 2.64 Billion USD | -0.79% |
| 2013 Q4 | 2.58 Billion USD | 0.0% |
| 2013 FY | 2.58 Billion USD | 1.6% |
| 2013 Q1 | 139 Million USD | 0.0% |
| 2012 FY | 2.54 Billion USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.65 Billion USD | -76.722% |
| Bausch Health Companies Inc. | 21.44 Billion USD | 78.084% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -513.607% |
| Elanco Animal Health Incorporated | 5.42 Billion USD | 13.335% |
| Perrigo Company plc | 3.32 Billion USD | -41.447% |
| Teva Pharmaceutical Industries Limited | 16.92 Billion USD | 72.24% |
| Zoetis Inc. | 4.76 Billion USD | 1.323% |